The valvulotome is a surgical device that is now used by vascular surgeons around the world. This scientific breakthrough is the brainchild of George D. LeMaitre, M.D., an inventor and the founder of LeMaitre Vascular. It was in 1983 that he started the business and the company got incorporated in June 1998.
Through his innovative works and the dedication of the group of experts in the company, LeMaitre Vascular continues to make a name in the industry it serves. The business innovates devices that are used for the treatment of peripheral vascular diseases. LeMaitre Vascular designs, develops and manufactures medical devices and implantable products that are primarily used in the field of vascular surgery. The company has several products that are now circulating in the markets in the United States and in some select international locations. These products are created to address various needs of vascular surgeons.
Part of the portfolio of the business is their valvulotomes, biologic grafts, biologic patches, carotid shunts, balloon catheters, radiopaque marking tape, anastomotic clips, laparoscopic cholecystectomy devices, angioscopes, vascular grafts, remote endarterectomy devices and powered phlebectomy devices. These products are marketed under various brand names, which include the Expandable LeMaitre Valvulotomoe, XenoSure biologic patch, the Pruitt F3 Carotid Shunt and the VascuTape Radiopaque Tape. To help the business market their products in various international locations, they continue to operate several subsidiaries, These companies include the LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Vascular GmbH, LeMaitre Vascular AS, and LeMaitre Vascular ULC, among others.
It is in Burlington, Massachusetts that the company holds its corporate office. The company is listed as one of the components of the Russell 3000 Index. LeMaitre Vascular, Inc. remains publicly traded on the NASDAQ Global Market and uses the ticker symbol LMAT to trade its common shares.
No comments:
Post a Comment